Study towards improving artemisinin-based combination therapies. Issue 7 (29th March 2021)

• Record Type: Journal Article
• Authors: Lyu, Hai-Ning; Ma, Nan; Meng, Yuqing; Zhang, Xing; Wong, Yin-Kwan; Xu, Chengchao; Liao, Fulong; Jiang, Tingliang; Tu, Youyou; Wang, Jigang
• Is Part Of: Natural product reports. Volume 38:Issue 7(2021)
• Page Start: 1243
• Page End: 1250
• Publication Date: 2021-03-29
• Subjects: Natural products -- Periodicals; Produits naturels -- Périodiques; 547.7
• DOI: 10.1039/d0np00079e
• Languages: English
• ISSNs: 0265-0568

Abstract

Abstract : This highlight provides a brief history of artemisinin in its journey from being a natural product to drug, as well as the continuous efforts to improve ACTs with better efficacy against the parasites, which have prolonged life cycles. Abstract : Covering: Up to 2020 Artemisinin has made a significant contribution towards global malaria control since its initial discovery. Countless lives have been saved by this unique and miraculous molecule. In 2006, artemisinin-based combination therapies (ACTs) were recommended by the World Health Organization (WHO) as the first-line treatment for uncomplicated malaria infection and have since remained as the mainstays of the antimalarial treatment. Even so, substantial efforts to pursue better curative effects for the treatment of malaria have never ceased, particularly with regards to the circumstances surrounding the appearance of delayed clearance of malaria parasites by 3 day ACT treatments in South-East Asian countries. Strategies to further optimize artemisinin-based therapies, including synthesizing better artemisinin derivatives, developing advanced drug delivery systems, and diversifying artemisinin partner drugs, have been proposed over the past few years. Here, we provide an updated account of the continuous efforts in improving ACTs for better efficacy in curing malarial infection.